15 March 2024
Helios Towers plc
("the Company")
Notification of transaction by persons discharging managerial responsibilities ("PDMRs")
The following notification made under Article 19(1) of the UK Market Abuse Regulation ("UK MAR") relates to the purchase of Company shares on behalf of certain PDMRs, and conditional awards to certain PDMRs to receive shares, to satisfy the deferred portion of the annual bonus in respect of the financial year ended 31 December 2023. This announcement is made in accordance with Article 19(3) of UK MAR.
This announcement should be read in conjunction with the Company's remuneration policy as set out in the 2022 Annual Report and Financial Statements and the Directors' Remuneration Report as set out in the 2023 Annual Report and Financial Statements (available on the 'Annual Report' page of the 'Investors' section of the Company's website: https://www.heliostowers.com/investors/annual-report/).
Enquiries: |
|
|
|
For investor enquiries | investorrelations@heliostowers.com |
| |
For media enquiries | Edward Bridges, Rob Mindell |
| FTI Consulting LLP |
| +44 (0)20 3727 1000 |
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities / person closely associated
| ||||
a) | Name
| Thomas Greenwood | |||
2 | Reason for the notification
| ||||
a) | Position/status
| Chief Executive Officer | |||
b) | Initial notification / Amendment
| Initial Notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a) | Name
| Helios Towers plc | |||
b) | LEI
| 213800DGC7GS4XCHCU30
| |||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a) | Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 1p each
GB00BJVQC708 | |||
b) | Nature of the transaction
| Acquisition of shares on behalf of the PDMR in connection with the deferral of annual bonus | |||
c) | Price(s) and volume(s) | | | | |
| | Price(s)
| Volume(s) | | |
| | GBP 0.833671 | 85,373 | | |
| | | | | |
d) | Aggregated information
- Aggregated volume
- Aggregated Price
- Aggregated Total
|
85,373
GBP 0.833671
GBP 71,172.99 | |||
e) | Date of the transaction
| 2024-03-14 | |||
f) | Place of the transaction | London Stock Exchange (XLON)
|
1 | Details of the person discharging managerial responsibilities / person closely associated
| |||||
a) | Name
| Manjit Dhillon | ||||
2 | Reason for the notification
| |||||
a) | Position/status
| Chief Financial Officer | ||||
b) | Initial notification / Amendment
| Initial Notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a) | Name
| Helios Towers plc | ||||
b) | LEI
| 213800DGC7GS4XCHCU30
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
| ||||
a) | Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 1p each
GB00BJVQC708 |
| |||
b) | Nature of the transaction
| Conditional award to the PDMR to receive shares in connection with the deferral of annual bonus |
| |||
c) | Price(s) and volume(s) | | | | |
|
| | Price(s)
| Volume(s) | |
| |
| | GBP 0.833671 | 55,797 | |
| |
| | | | |
| |
d) | Aggregated information
- Aggregated volume
- Aggregated Price
- Aggregated Total
|
55,797
GBP 0.833671
GBP 46,516.34 |
| |||
e) | Date of the transaction
| 2024-03-14 |
| |||
f) | Place of the transaction | Outside a trading venue
|
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.